Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses

Pharmacogenetics and Genomics

Volumn 24, Issue 5, 2014, Pages 231-237

  Wheeler, Heather E ^a   González Neira, Anna ^b   Pita, Guillermo ^b   De La Torre Montero, Julio Cesar ^c   Alonso, Rosario ^b   Lopez Fernandez, Luis A ^d   Alba, Emilio ^e   Martín, Miguel ^d   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; GELATINASE A; HOMEODOMAIN PROTEIN; IROQUOIS HOMEOBOX PROTEIN 6; UNCLASSIFIED DRUG; DEOXYCYTIDINE; FLUOROURACIL;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; FEMALE; GENETICS; GENOMICS; PATHOLOGY; PHARMACOGENETICS;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HAND-FOOT SYNDROME; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84898548767     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000037     Document Type: Article

References (45)

1. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007; 11:238-246.
2. Janusch M, Fischer M, Marsch W, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome - a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006; 16:494-499.
3. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1:225-234.
4. Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 2011; 10:159-169.
5. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75:11-17.
6. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. Firstline oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566-575.
7. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118-2123.
8. Caronia D, Martin M, Sastre J, de la Torre J, Garcia-Saenz JA, Alonso MR, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011; 17:2006-2013.
9. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-3468.
10. Gonzalez-Haba E, Garcia MI, Cortejoso L, Lopez-Lillo C, Barrueco N, Garcia-Alfonso P, et al. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 2010; 11:1715-1723.
11. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013; 108:2505-2515.
12. Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki AM. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol 2010; 65:403-406.
13. Ribelles N, Lopez-Siles J, Sanchez A, Gonzalez E, Sanchez MJ, Carabantes F, et al. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab 2008; 9:336-343.
14. van Huis-Tanja LH, Gelderblom H, Punt CJ, Guchelaar HJ. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. Pharmacogenet Genomics 2013; 23:208-218.
15. Dolan ME, Newbold KG, Nagasubramanian R,Wu X, Ratain MJ, Cook EH Jr, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004; 64:4353-4356.
16. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009; 4:e7765.
17. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 2004; 101:11809-11814.
18. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 2012; 13:55-70.
19. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 2013; 14:23-34.
20. Cox NJ, Gamazon ER, Wheeler HE, Dolan ME. Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther 2012; 92: 425-427.
21. Wheeler HE, Gamazon ER,Wing C, Njiaju UO, Njoku C, Baldwin RM, et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 2013; 19:491-499.
22. O'Donnell PH, Stark AL, Gamazon ER,Wheeler HE, McIlwee BE, Gorsic L, et al. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 2012; 118:4063-4073.
23. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, et al. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 2008; 82:631-640.
24. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 2009; 84:210-223.
25. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2013; 13:35-43.
26. Abecasis GR, Cookson WO, Cardon LR. Pedigree tests of transmission disequilibrium. Eur J Hum Genet 2000; 8:545-551.
27. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006; 2:e190.
28. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44:955-959.
29. Degner JF, Marioni JC, Pai AA, Pickrell JK, Nkadori E, Gilad Y, et al. Effect of read-mapping biases on detecting allele-specific expression from RNA-sequencing data. Bioinformatics 2009; 25:3207-3212.
30. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, et al. SCAN: SNP and copy number annotation. Bioinformatics 2010; 26:259-262.
31. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M, et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet 2011; 7:e1002003.
32. Diaz-Hernandez ME, Bustamante M, Galvan-Hernandez CI, Chimal-Monroy J. Irx1 and Irx2 are coordinately expressed and regulated by retinoic acid, TGFbeta and FGF signaling during chick hindlimb development. PLoS One 2013; 8:e58549.
33. McDonald LA, Gerrelli D, Fok Y, Hurst LD, Tickle C. Comparison of Iroquois gene expression in limbs/fins of vertebrate embryos. J Anat 2010; 216:683-691.
34. Kim KH, Rosen A, Bruneau BG, Hui CC, Backx PH. Iroquois homeodomain transcription factors in heart development and function. Circ Res 2012; 110:1513-1524.
35. Shih B, Brown JJ, Armstrong DJ, Lindau T, Bayat A. Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue. Hand (NY) 2009; 4:294-301.
36. Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 2003; 4:461-485.
37. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 2011; 21:237-242.
38. Agren MS. Gelatinase activity during wound healing. Br J Dermatol 1994; 131:634-640.
39. Fleischmajer R, Kuroda K, Hazan R, Gordon RE, Lebwohl MG, Sapadin AN, et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol 2000; 115:771-777.
40. Marzano AV, Cugno M, Trevisan V, Lazzari R, Fanoni D, Berti E, et al. Inflammatory cells, cytokines and matrix metalloproteinases in amicrobial pustulosis of the folds and other neutrophilic dermatoses. Int J Immunopathol Pharmacol 2011; 24:451-460.
41. Kim CH,Waldman ID, Blakely RD, Kim KS. Functional gene variation in the human norepinephrine transporter: association with attention deficit hyperactivity disorder. Ann N Y Acad Sci 2008; 1129:256-260.
42. Buttenschon HN, Jacobsen IS, Grynderup MB, Hansen AM, Kolstad HA, Kaerlev L, et al. An association study between the norepinephrine transporter gene and depression. Psychiatr Genet 2013; 23:217-221.
43. Houston JP, Lau K, Aris V, Liu W, Fijal BA, Heinloth AN, et al. Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis. J Clin Psychiatry 2012; 73:878-885.
44. Lin Z, Madras BK. Human genetics and pharmacology of neurotransmitter transporters. Handb Exp Pharmacol 2006; 175:327-371.
45. Kambeitz J, Romanos M, Ettinger U. Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics J 2013; 14:77-84.